Global Follicle Stimulating Hormone Market - 2023-2030

Global Follicle Stimulating Hormone Market - 2023-2030

The Global Follicle Stimulating Hormone Market reached US$ 1.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.9 billion by 2030. The global follicle stimulating hormone market is expected to exhibit a CAGR of 5.8% during the forecast period (2023-2030). The increasing prevalence of infertility, growing awareness and acceptance of fertility treatments, and growing aging population are driving the growth of the follicle stimulating hormone market trends.

The global follicle stimulating hormone (FSH) market has been expanding continuously in recent years. FSH, a reproductive hormone, is essential in regulating the menstrual cycle and encouraging the growth of ovarian follicles in women. It is commonly utilized in fertility treatments and hormone replacement therapies.

The global follicle stimulating hormone market scope comprises components encompassing recombinant FSH, urinary FSH, infertility treatment, assisted reproductive technology and others, which has increased usage of follicle stimulating hormone market share. The global market for follicle stimulating hormones is expanding as a result of factors including technological advancements in fertility treatment procedures, increasing awareness and acceptance of fertility treatments, and increasing focus on reproductive health.

Market Dynamics

An Increase in Aging Population Drive the Growth of the Follicle Stimulating Hormone Market

The global FSH market is being driven by an aging population. Individuals' fertility potential reduces as they age, resulting in an increased demand for fertility treatments, especially FSH treatment, to address age-related infertility. The increased understanding and acceptability of fertility treatments, as well as the trend of postponed childbirth, have all contributed to the market's rise.

For instance, according to World Health Organization (WHO) 2022 report, by 2030, about one out of every six people on the planet will be 60 or older. Within this time span, the share of the world population aged 60 and up is expected to increase from 1 billion in 2020 to 1.4 billion. Overall, the aging population's desire for parenthood and the need for fertility solutions drive the growth of the global follicle stimulating hormone market.

Growing Adoption of Assisted Reproductive Technology is the Major Driver in the Global Follicle Stimulating Hormone Market

The use of assisted reproductive technology (ART) includes a variety of medical techniques designed to aid individuals in achieving pregnancy. In vitro fertilization (IVF) is one of the most well-known types of ART, in which eggs and sperm are mixed in a laboratory setting to fertilize and then implant the resulting embryos into the uterus.

Furthermore, the rising prevalence of polycystic ovary syndrome (PCOS) has contributed to an increase in infertility. PCOS is a common cause of female infertility, affecting roughly 6% to 12% of women of reproductive age in the United States, according to the Centers for Disease Control and Prevention (CDC) 2022 statistics. The continued prevalence of PCOS will drive demand for infertility treatments, consequently propelling the global follicle stimulating hormone market over the forecast period.

Significant Emotional and Psychological Toll on Individuals Due to Fertility Challenges and the Need for Assisted Reproductive Technologies Will Hamper the Growth of the Market.

The psychosocial consequences of infertility and ART are extensive, and they can have a significant impact on patients' sense of self-identity and personal agency, mental well-being, sexual and marital relationships, reproductive efficiency, treatment compliance, and pregnancy outcomes. Between 25% and 65% of women receiving ART experience clinical stress, anxiety, and negative emotions such as low self-esteem or guilt. Hence, the above mentioned factors are limiting the follicle stimulating hormone market’s growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The conflict between Russia and Ukraine has the potential to cause supply chain interruptions, uncertainty, and instability, which could affect the worldwide follicle-stimulating hormone (FSH) market. FSH product development and clinical trials would be impacted, which would slow down innovation. Market participants might look for FSH production diversification and alternate sources.

Furthermore, pricing and demand may be impacted by the economic impact, which includes currency fluctuations and modifications to market dynamics. There may be regional variances, with nations closer to the conflict feeling the effects more immediately. In order to navigate potential obstacles and seize possibilities in the FSH market, industry stakeholders must maintain constant observation and flexibility.

Segment Analysis

The global follicle stimulating hormone market is segmented based on type, application, end user, and region.

Recombinant FSH Segment Accounts for 56.3% of the Market Share Owing to Rising Demand for it.

Recombinant FSH products are produced in the laboratory and have various advantages over urinary-derived FSH products. One significant advantage is their superior purity, as they are free of contaminants commonly present in urinary-derived FSH. This provides consistent potency and reduces the possibility of contamination.

Gonal-f, Follistim, and Puregon are examples of rFSH medicines that have a sizable market share. Because of their effectiveness and high-quality standards, these brands have gained favor among healthcare providers and patients. They are trusted choices in reproductive treatments, including regulated ovarian stimulation in ART procedures such as IVF.

For instance, Bharat Serums and Vaccines Limited is conducting a clinical trial using Recombinant Human Follicle Stimulating Hormone for treating infertility. About 250 women in the age group of 20 to 39 years have participated in this trial and currently, it is in phase 3 trial and the estimated completion of the trial is in November 2023. Therefore, owing to the above reasons, the recombinant FSH segment is expected to drive the market growth over the forecast period.

Geographical Analysis

North America Accounted for Approximately 41.4% of the Market Share Owing to the Investment by the Major Players’ Presence in this Region

North America's market dominance has been facilitated by the presence of established and influential companies, increased awareness and an increase in the rate of infertility growth which is related to unhealthy lifestyles and diets. Also, the rising healthcare costs and the widespread use of FSH products, along with an increase in inpatient visits to gynecologists are driving the market demand in North America.

Furthermore, Fertility Awareness Methods (FAMs), for example, are recognized by the United States Agency for International Development (USAID) as modern contraceptives that meet specified requirements, such as safety, effectiveness in preventing conception, and a basic grasp of reproductive biology.

FAMs have been evaluated in well-designed studies to determine their efficacy under a variety of situations. FAMs also have the advantage of not requiring clinical involvement and can be delivered through a variety of service delivery methods. As a result of the aforementioned factors, the North American region is expected to hold the biggest market share throughout the projection period.

Competitive Landscape

The major global players in the follicle stimulating hormone market include Merck Serono, Creative BioMart, Midas Pharma GmbH, GenPharm, Trumac Healthcare, Livzon, Shanghai Techwell Biopharmaceutical Co., Ltd., Merck Sharp & Dohme Corp, Lee Biosolutions, Inc, and BIOGENIX INC.PVT.LTD.

Why Purchase the Report?
• To visualize the global follicle stimulating hormone market segmentation based on type, application, end user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Follicle stimulating hormone market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global follicle stimulating hormone market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies